Drug Approval | July 18, 2022
Orchid Pharma updates on PLI scheme benefits for its subsidiary
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Subscribe To Our Newsletter & Stay Updated
